Every 10-Q that ALLURION TECHNOLOGIES INC (ALUR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ALUR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALUR filings page.
Allurion Technologies reported a challenging first quarter of 2026. Revenue was $2.9 million, down from $5.6 million a year earlier, as sales declined across several geographies. The company posted a net loss of $6.1 million compared with a $1.5 million loss in the prior-year quarter, partly driven by a $4.1 million warrant inducement expense.
Cash and cash equivalents were $5.1 million as of March 31, 2026, while total assets were $14.0 million against total liabilities of $91.9 million, resulting in a stockholders’ deficit of $77.9 million. The balance sheet includes a $48.8 million Revenue Interest Financing liability and $28.6 million of RTW Convertible Notes, both carried at fair value.
Management discloses substantial doubt about Allurion’s ability to continue as a going concern within one year, citing recurring operating losses, negative operating cash flows, covenant noncompliance under its credit facilities, and the need for additional capital. Cost reductions from prior restructuring actions sharply lowered operating expenses, but they did not offset weaker revenue and financing-related fair value movements.
Allurion Technologies (ALUR) reports sharply weaker results for the quarter ended September 30, 2025. Revenue fell to $2.7 million from $5.4 million a year earlier, while the company swung from net income of $8.7 million to a net loss of $11.9 million, driven by lower sales and continued operating expenses. For the first nine months of 2025, revenue declined to $11.6 million from $26.5 million, with a net loss of $22.7 million versus net income of $2.4 million in the prior-year period.
Allurion ended the quarter with $6.1 million in cash and cash equivalents and total assets of $18.1 million, against total liabilities of $101.1 million, including a $49.9 million Revenue Interest Financing liability and $32.2 million of convertible notes payable. Stockholders’ deficit widened to $82.9 million, even after increasing common shares outstanding to 7,767,027 from 2,710,607 at December 31, 2024.
Allurion Technologies amended its quarterly report to reflect a restatement and adjustments tied to a Reverse Stock Split and the closing of its Business Combination with Compute Health. The filing discloses material weaknesses in internal control over financial reporting and describes remediation steps including hiring accounting staff, implementing a new ERP, and engaging a national accounting firm.
The company completed several financing and capital transactions: a PIPE investment of $37.9 million, a Public Offering consummated July 1, 2024, amended convertible note arrangements, and revenue interest financing that pays 6.0% of annual net sales through 2026 and up to 10.0% thereafter until 2030. The Allurion Balloon sales were suspended in France and remediation is underway; the company also disclosed NYSE non-compliance and submitted a plan to regain compliance.
Allurion Technologies amended its Form 10-Q to restate prior interim financials and reflect a 1-for-25 reverse stock split effective January 3, 2025. The filing discusses the completed Business Combination with Compute Health and conversion/recapitalization mechanics that produced Allurion common stock and warrants, notes the Company completed a Public Offering on July 1, 2024, and records a $37.9 million PIPE investment. The company discloses material weaknesses in internal control over financial reporting and remediation actions underway, and reports a suspension of Allurion Balloon sales in France in August 2024. Debt and convertible note amendments, warrant conversions and derivative accounting for certain PIPE and conversion options are described.
Allurion Technologies, Inc. amended its quarterly report to reflect a reverse stock split and provides details on the previously completed Business Combination with Compute Health Acquisition Corp., related equity recapitalizations, and follow-on financing arrangements. The filing discloses a $37.9 million PIPE investment and multiple convertible note, term loan and revenue-interest financing arrangements with detailed conversion, royalty and reset provisions that could affect future dilution and cash obligations.
The company disclosed prior-period adjustments related to retroactive share restatements from the Business Combination, and identified material weaknesses in internal control over financial reporting with described remedial steps including hiring accounting staff, implementing a new ERP, additional review controls, and engagement of a national accounting firm. The filing also discusses contingent consideration valuation, warrant liabilities, and various debt modifications and covenant features.
Allurion Technologies reported operational and financial updates alongside a restatement and remediation efforts for internal control weaknesses. The company is addressing a restatement of prior financial statements and disclosed material weaknesses in internal control over financial reporting while describing steps taken to remediate those weaknesses, including hiring experienced accounting staff, implementing a new ERP system, and engaging a national accounting firm. Management announced a strategic restructuring expected to reduce the workforce by about 70 employees (~65% of staff) with estimated severance-related charges of approximately $1.5 million. Financing activity included multiple private placements and offerings that raised net proceeds of $2.5 million (RTW private placement), $5.8 million (January 2025 offering), and $3.9 million (February 2025 offering), plus a Leavitt placement of $1.3 million. The company described amended revenue interest financing that increases payments from 6.0% up to 10.0% of annual net sales after 2027 and various conversion features tied to PIPE and RTW convertible notes. The filing discloses a pending litigation claim seeking approximately $2.5 million and details product, regulatory, and commercialization initiatives including a GLP-1 program, distribution transitions, and a planned multi-center study in Europe.
Allurion Technologies (ALUR) amended its quarterly report to reflect a prior restatement and to disclose post-business-combination corporate and financing activity. The company completed a business combination with Compute Health and applied a reverse stock split, which changed warrant and share conversion ratios. It disclosed multiple equity and warrant offerings closed in January and February 2025 that raised net proceeds of $5.8 million and $3.9 million, respectively, and additional private placements raising $2.5 million and $1.3 million. The company described amendments to a revenue interest financing agreement that increased revenue-interest rates and related derivative accounting, conversions and debt modifications, and recorded related liabilities and remeasurements. Allurion operates in ~50 countries, provides the Allurion Program and App for remote patient monitoring, and disclosed remediation steps for previously identified internal control weaknesses and an NYSE cure plan.